SCHEMBL16032467

SCHEMBL16032467

O=C1NCC(c2ccccc2)N1Cc1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SIGMAR1 Q99720 1/20 0.49
TP53 P04637 1/20 0.47
MDM2 Q00987 1/20 0.47
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HSD17B2 P37059 1/20 0.44
CETP P11597 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
GLA P06280 1/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
OPRM1 P35372 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28046393 0.74 SIGMAR1 (0.47) MAPTCYP2C9CYP2C19SIGMAR1TP53
SCHEMBL7347383 0.73 SLC6A3 (0.43) TP53MDM2SLC6A3ATM
SCHEMBL13946010 0.71 CHRM2 (0.83) MAPTCYP2C9CYP2C19SIGMAR1KDM4E
SCHEMBL11707386 0.71 MAPT (0.56) MAPTCYP2C9CYP2C19SIGMAR1KMT2A
SCHEMBL7352920 0.70 ATM (0.49) KMT2AATMMEN1
SCHEMBL4441163 0.69 CETP (0.46) MAPTCETPALDH1A1HTTATM
SCHEMBL6828413 0.69 EHMT2 (0.47) CYP2C19SIGMAR1KMT2ATDP1KDM4E
SCHEMBL9826474 0.69 ATM (0.39) SLC6A3ATMCHRM2CHRM3
SCHEMBL16031831 0.68 SLC6A3 (0.58) MAPTCYP2C9CYP2C19TP53MDM2
SCHEMBL8293421 0.68 EHMT2 (0.46) CYP2C19KMT2ATDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970215-B1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND (DE) 2019-04-17 EP disclosed
US-9656955-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-23 US disclosed
US-9650334-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-16 US disclosed
EP-2970215-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-20 EP disclosed
WO-2014140310-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 WO disclosed
US-20140275086-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 US disclosed
US-20140275087-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275086-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC6A7, GFPT1, SUGT1 MAPT 613/4885CYP2C9 684/4885CYP2C19 493/4885
US-20140275087-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC6A7, GFPT1, SUGT1 MAPT 613/4885CYP2C9 684/4885CYP2C19 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.